Merck Enters into a Development Agreement with Daiichi for Antibody Drug Conjugates
On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. Merck has invested $5.5 billion to jointly develop three of its candidate cancer drugs and is likely to invest up to $22 billion in addition depending on the success of the cell-targeting therapies.
Patritumab deruxtecan is being evaluated for the treatment of EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor (TKI) and platinum-based therapies. Ifinatamab deruxtecan is under study as a monotherapy in Phase II in patients previously treated extensive-stage small cell lung cancer. Raludotatug deruxtecan (R-DXd) is being assessed in a first-in-human Phase I trial for patients with advanced ovarian cancer.
The three ADCs are designed to target and deliver a cytotoxic payload inside cancer cells that express a specific cell surface antigen, using Daiichi Sankyo’s DXd ADC technology. Each ADC consists of a monoclonal antibody attached to a number of topoisomerases I inhibitor payloads via tetrapeptide-based cleavable linkers.
According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72 billion in 2023 and is expected to grow at CAGR of 9.63% during the forecast period.
For detailed insights about this domain, check out our report on Antibody Drug Conjugate Market or email sales@rootsanalysis.com
You may also be interested in the following titles:
Fc Fusion Protein – A New Approach to Drug Therapy
Antibody Drug Conjugates Market Update: Ambrx and NovoCodex Collaborate
ANTIBODY DRUG CONJUGATES: THE RECENT APPROVALS
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.